Regula Repeatedly Named a Representative Vendor in Gartner Market Guide for Identity Verification
14.9.2023 10:00:00 EEST | Business Wire | Press release
The identity verification industry has evolved significantly in recent years, expanding its scope beyond traditional Know Your Customer (KYC) processes. As IDV is becoming the new norm, more identity verification providers are vying for the attention of potential customers.
While the market is becoming a buyer’s market, it can also be confusing because of the many seemingly similar offers. As Gartner notes, “It is challenging for end-user organizations to select a vendor in a crowded market. Many tend to simply select vendors with experience and presence in their country or region.” However, it’s more important than ever before to have comprehensive selection criteria when choosing a solution.
The two pillars of identity verification: Document authenticity and liveness check
In the era of digital nomadism, it’s an advantage for a vendor to have global coverage of supported IDs. Not only is it a plus for user experience, but it also provides qualitative attributes for effective fraud prevention.
Also, remote interactions are paramount in most scenarios. A proper solution should offer an extensive set of document verification checks, from automatic document type recognition to NFC-based verification (the most trustworthy method). Concerning the latter, an effective solution should allow re-verification of electronic chips by processing results on a server, thus eliminating the risk of accepting a tampered ID.
As for binding the ID to the actual individual, it may already be not enough to ask users to take selfies (passive liveness check). Organizations need to be able to detect various biometric fraud, including injection attacks, and be able to compare live biometrics with the photo on the document and the data encoded in the chip embedded in the ID.
All in all, it’s crucial for a vendor to deliver a complete verification solution that tackles everything mentioned above. These key tasks are covered by Regula’s products acknowledged in the report—Regula Document Reader SDK and Regula Face SDK. Together, they form a solid future-proof foundation for reliable identity verification.
Beyond the basics
Given the evolving landscape of security challenges and the growing demand for comprehensive solutions, organizations are looking for tools that can offer more than just the basics. Vendors are expected to stand out by adding more value through augmenting core capabilities with novel implementation approaches and the ability to handle AI-enabled attack vectors.
According to Regula’s latest survey, in the past year, 37% of organizations encountered incidents of deepfake voice fraud, while 29% fell victim to deepfake videos. The increasing accessibility of artificial intelligence technology for crafting deepfakes is amplifying these risks, posing a significant challenge for both businesses and individuals.
Regula has taken a proactive approach to fortifying defenses against this threat by investing in a forward-looking roadmap. "When it comes to detecting deepfakes, we believe that neural networks can be valuable for defensive purposes, as long as they come with other anti-fraud measures that focus on physical and dynamic parameters,” says Henry Patishman, VP of Identity Verification Solutions at Regula. “These include face liveness checks, document liveness checks, optically variable security elements, and more. It's still challenging to create deepfakes that show the expected dynamic behavior. Verifying the liveness of an object can provide a crucial advantage against fraudsters. Additionally, cross-referencing user information with biometric checks and recent transaction history can enhance the verification process."
*Gartner, Market Guide for Identity Verification, Akif Khan, 7 September 2023
About Gartner
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Proofing and Affirmation in 2022. Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230915253195/en/
Contact information
Kristina – ks@regulaforensics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
